Jci_page_head_homepage_01 Jci_page_head_homepage_02
Medhat Shehata, Josef D. Schwarzmeier, Martin Hilgarth, Rainer Hubmann, Markus Duechler, Heinz Gisslinger
Published in Volume 113, Issue 5
J Clin Invest. 2004; 113(5):676–685 doi:10.1172/JCI19540
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 3

Secreted and intracellular TGF-β1 in BM cells. (A) BMMCs of HCL patients produced significantly higher amounts of TGF-β1 throughout the incubation than BMMCs of HDs. (B) The amounts of TGF-β1 secreted by BMSCs and BMFs of HCL patients were comparable to the amounts secreted by HD cells. (C and D) Double immunofluorescence staining of BM sections of an HCL patient (representative of four patients tested) shows the colocalization of CD22 (an HC marker) (C) and TGF-β1 (D). (E and F) Cytospin preparation of BMMCs (>90% HCs) double-stained with antibody against CD103 (B-ly7, a specific HC marker) and against TGF-β1 (E and F), confirming the presence of TGF-β1 in the HCs. Original magnification, ×100 (C and D) and ×400 (E and F).